Cambridge Healthtech Institute’s Third Annual

Companion Diagnostics

Strategies for Guiding Treatment and Improving Health

March 10-11, 2016 | Hilton San Francisco Union Square| San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

 

The introduction of new clinical trial protocols, next-generation sequencing, reimbursement constraints, immunotherapy treatments and changing regulatory guidelines are all impacting the progress of companion diagnostics. Conflicting demands on the system make it difficult to assess the best way to move forward in matching patients with a treatment regimen that is suited to them based on genomic information. The standard of care in oncology demonstrates how powerful this change and adaptation can be to the practice of personalized medicine, but developing a comprehensive and successful plan requires careful consideration of the factors at play. Experts in the field will assemble for the Companion Diagnostics symposium to address these questions and shed light on both the technology development as well as implementation.

Who should attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from large Pharma, Biotechs and Academia working in fields of Companion Diagnostics, Business Development, R&D, Clinical Research, in vitro Diagnostics, Personalized Healthcare, Targeted Therapies and Oncology.

Topics will include, but are not limited to:

  • Evaluating new business models for the changing environment in companion diagnostics
  • Managing reimbursement, regulation, and patient risk
  • Curating information to measure outcomes
  • Appraising a systems approval of companion diagnostics
  • Amalgamating and synthesizing data for the physician
  • Building infrastructure to support immunotherapy
  • Employing advanced analytics for big data and personalized medicine
  • Reviewing newest companion diagnostic products on the market
  • Analyzing impact of payment schemes, US and abroad

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is August 28, 2015.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
T: 781-972-5464
E: clingham@healthtech.com

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z)
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com

Premier Sponsors:  

Bina Technologies

Coyote

Elsevier   

Jackson Laboratory - small logo 

 NanoString2   

 Precision for Medicine 

SeraCare(2)

Silicon Biosystems

Thomson Reuters-Large